Reich, K., Warren, R., Iversen, L., Puig, L., Pau‐Charles, I., Igarashi, A., . . . Thaçi, D. (2019). Long‐term efficacy and safety of tildrakizumab for moderate‐to‐severe psoriasis: Pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks. Br J Dermatol.
Chicago ZitierstilReich, K., et al. "Long‐term Efficacy and Safety of Tildrakizumab for Moderate‐to‐severe Psoriasis: Pooled Analyses of Two Randomized Phase III Clinical Trials (reSURFACE 1 and ReSURFACE 2) Through 148 Weeks." Br J Dermatol 2019.
MLA ZitierstilReich, K., et al. "Long‐term Efficacy and Safety of Tildrakizumab for Moderate‐to‐severe Psoriasis: Pooled Analyses of Two Randomized Phase III Clinical Trials (reSURFACE 1 and ReSURFACE 2) Through 148 Weeks." Br J Dermatol 2019.